Lv1
40 积分 2025-06-03 加入
A Randomized, Double‐Blind, Parallel Controlled, Single‐Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects
7天前
已完结
A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects
7天前
已完结
Artritis reumatoide
11天前
已完结
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I study
1个月前
已完结
Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study
1个月前
已完结
A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01)
2个月前
已完结
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
2个月前
已完结
[2024 Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis]
2个月前
已完结
Depression in Patients with Rheumatoid Arthritis: Unmasking the Hidden Burden
2个月前
已关闭
Advancement in contemporary diagnostic and therapeutic approaches for rheumatoid arthritis
2个月前
已完结
皖公网安备34019202002308
